Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 3/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7367925 | 0.86 | DPP7 (0.47) | IDH1DPP7DPP4MEN1KMT2A | |
| SCHEMBL6638863 | 0.85 | DPP4 (0.53) | IDH1DPP7DPP4MEN1KMT2A | |
| SCHEMBL3627699 | 0.83 | DPP4 (0.46) | IDH1DPP7DPP4MEN1KMT2A | |
| SCHEMBL3060340 | 0.81 | HCAR3 (0.49) | IDH1DPP7DPP4MEN1KMT2A | |
| SCHEMBL2638951 | 0.79 | DPP7 (0.47) | IDH1DPP7DPP4MEN1KMT2A | |
| SCHEMBL3049238 | 0.79 | HCAR3 (0.51) | IDH1DPP7DPP4DPP8KDM4E | |
| SCHEMBL1726095 | 0.79 | DPP7 (0.50) | IDH1DPP7DPP4MEN1KMT2A | |
| SCHEMBL1119557 | 0.79 | DPP7 (0.50) | IDH1DPP7DPP4MEN1KMT2A | |
| SCHEMBL2638953 | 0.79 | DPP7 (0.47) | IDH1DPP7DPP4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1119507 | 0.77 | DPP7 (0.49) | IDH1DPP7DPP4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063221-B2 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | claimed |
| CN-100509833-C | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2009-07-08 | — | — | CN | claimed |
| EP-2013182-A2 | AMINOQUINOLONES AS GSK-3 INHIBITORS | Activx Biosciences, Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | claimed |
| WO-2007106537-A2 | AMINOQUINOLONES AS GSK-3 INHIBITORS | ACTIVX BIOSCIENCES, INC. (US) | 2007-09-20 | — | — | WO | claimed |
| CN-1630661-A | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2005-06-22 | — | — | CN | claimed |
| EP-1523316-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND AN INSULIN SECRETOR ENHANCER OR AN INSULIN SENSITIZER | Novartis AG (CH) | 2005-04-20 | — | — | EP | claimed |
| WO-2004071454-A2 | SUBSTITUTED AZETIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS INC. (US) | 2004-08-26 | — | — | WO | claimed |
| EP-0937040-B1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2004-07-21 | — | — | EP | claimed |
| US-20040002519-A1 | Combination of organic compounds | DAMON ROBERT EDSON (US) | 2004-01-01 | — | — | US | claimed |
| WO-2003080070-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITTOR AND AN INSULIN SECRETOR ENHANCER OR AN INSULIN SENSITIZER | NOVARTIS AG (CH) | 2003-10-02 | — | — | WO | claimed |
| US-6011155-A | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | NOVARTIS AG (CH) | 2000-01-04 | — | — | US | claimed |
| CN-1236361-A | N-substituted 2-cyanopyrrolidines | NOVARTIS AG (CH) | 1999-11-24 | — | — | CN | claimed |
| EP-0937040-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | Novartis AG (CH) | 1999-08-25 | — | — | EP | claimed |
| WO-1998019998-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 1998-05-14 | — | — | WO | claimed |
| EP-2013182-B1 | AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2383271-B1 | Aminoquinolones as GSK-3 Inhibitors | KYORIN SEIYAKU KK (JP) | 2013-07-10 | — | — | EP | disclosed |
| CN-1236361-A | N-substituted 2-cyanopyrrolidines | NOVARTIS AG (CH) | 1999-11-24 | — | — | CN | disclosed |
| EP-0937040-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | Novartis AG (CH) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998019998-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | IDH1 887/4885DPP7 1532/4885DPP4 1015/4885 |
| US-20040002519-A1 | Combination of organic compounds | HMGCR, SRD5A2, HSD17B7 | IDH1 181/4885DPP7 446/4885DPP4 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.